CClinicalTrials.gg
Status unknownNCT02553668Updated Sep 17, 2015

Proteomics for Identification of Hyperoxia-induced Changes in Protein Expression

An interventional study of Oxygen (FiO2 1,0) and Facemask in Hyperoxia, sponsored by University Hospital of Cologne. Status unknown. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-09-17.

Sponsored by University Hospital of Cologne · Not applicable, Interventional, and Basic science

The sponsor has not verified this record recently (last verified Sep 2015), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years to 50 Years
Sex
All
01

Study summary

Aim of the present study is to investigate the influence of hyperoxia on the protein expression using the differential analysis of protein expression in tissues (proteomics). In the study, blood and urine samples will be collected from participants who undergo a short term hyperoxia using 100% oxgen for 3 hours.

Here, gel electrophoresis, protein separation and mass spectroscopy allow to identify affected proteins. Based on these results, different induction factors of proteins will be determined and then assessed using a bioinformatic network analysis regarding the cellular influence.

Read the detailed description

Oxygen is necessary to sustain human life and is used for energy production by oxidation in the mitochondria. Application of oxygen not only increases saturation in the patient's blood, but also has various secondary effects. It is therefore used to treat diseases that impairs body's ability to take up and use oxygen. But even healthy people can suffer from hypoxia when they ascend to high altitude. Here, altitude sickness can lead to potentially fatal complications such as high altitude cerebral edema or high altitude pulmonary edema. Since hypoxia can have disastrous consequences, hyperoxia is often tolerated in many pre- and in-hospital situations.

Whereas the effects of hypoxia are well studied, especially publications in the last decade have led to a new perspective on oxygen application. Besides pathophysiological changes as the peripheral vasoconstriction or reduction of contractility, especially changes on cellular level seem to be of great importance. Here, oxidative stress and change of protein synthesis in various organ are focus of current studies.

The differential analysis of protein expression in tissues (proteomics) is an important approach for better understanding of the negative effects of hyperoxia. Especially for patients with long-term high oxygen demand the knowledge of cellular changes during hyperoxia can result in new therapeutic approaches and a reduction in the rate of complications.

In the present molecular biology study urine and blood samples of healthy volunteers will be collected at specified times after short-term exposure to oxygen. These samples will be analyzed after the study using the differential analysis of protein expression. The aim of this study is to investigate the effects of oxygen on the cell functions by analyzing and subsequent bioinformatic processing of differentially regulated proteins in the blood and urine.

After checking the inclusion and exclusion criteria biometric data of the test persons are collected.

Before short-term hyperoxia a sample collection of blood and urine will be performed. Here the participants are taken 5 ml of venous blood from the cephalic vein under sterile conditions. To obtain the urine sample spontaneous urine of participants is used. The samples are immediately centrifuged and flash frozen at -80°C. In order to exclude impairment of the lung prior to the short-term hyperoxia a pulmonary function test is carried out by using a hand spirometer.

To induce hyperoxia subjects inhale 100% oxygen for 3 hours through a face mask.

After carrying out the short term hyperoxia the follow up phase takes place. In this phase blood and urine samples from the subjects will be obtained directly after the hyperoxia (T0), on day 1 (T1), day 3 (T3), day 7 (T7), day 14 (T14), day 21 (T21) and day 28 (T28) after oxygen exposure. All samples will be centrifuged immediately after collection and flash frozen at -80 ° C. To exclude hyperoxia-induced lung impairments, a spirometry is performed during the follow up.

After the samples of all subjects were collected the analysis of the samples will be carried out using Proteomics.

02

Conditions studied

  • Hyperoxia

Browse trials for

Keywords

  • Proteomics
  • Oxygen
  • Pathways
03

In context

Hyperoxia

124 studies on the registry are indexed under Hyperoxia; 21 are open to participants now.

This study's planned enrollment of 40 is below the median of 48 across 99 interventional studies indexed under Hyperoxia.

Browse Hyperoxia studies →

Lead sponsor

University Hospital of Cologne is the lead sponsor of 42 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • American Society of Anesthesiologists (ASA) 1
  • >18 years
  • \< 50 years

Exclusion criteria

Exclusion Criteria:

  • American Society of Anesthesiologists (ASA) > 1
  • pregnant
  • \<18 years
  • > 50 years
  • frequent or recent drug intake
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Hyperoxia

    Participants receive 100% oxygen

    Drug: Oxygen (FiO2 1,0) · Device: Facemask

Interventions

  • DrugOxygen (FiO2 1,0)

    Participants will inhale Oxygen (FiO2 1,0) via Facemask for 3 hours.

  • DeviceFacemask
06

What researchers measure

Primary outcomes

  1. Comparison of proteomics changes before and after short-term hyperoxia

    Time frame: 4 weeks

Secondary outcomes

  1. Spirometry Results: Forced vital capacity (FVC) [L]

    Spirometry will be used as a measure of safety to rule out adverse events of oxygen to the lung.

    Time frame: 2 days

  2. Spirometry Results: Forced expiratory volume at one second (FEV1) [L]

    Spirometry will be used as a measure of safety to rule out adverse events of oxygen to the lung.

    Time frame: 2 days

  3. Spirometry Results: Forced expiratory flow (FEF25-75) [L/s]

    Spirometry will be used as a measure of safety to rule out adverse events of oxygen to the lung.

    Time frame: 2 days

  4. Spirometry Results: Peak expiratory flow (PEF) [L/s]

    Spirometry will be used as a measure of safety to rule out adverse events of oxygen to the lung.

    Time frame: 2 days

  5. Vital parameter: Respiratory rate (RR) [1/min]

    Vital parameters will be used as a measure of safety to rule out adverse events of oxygen to the vascular system.

    Time frame: 3 hours

  6. Vital parameter: Heart rate (HR) [1/min]

    Vital parameters will be used as a measure of safety to rule out adverse events of oxygen to the vascular system.

    Time frame: 3 hours

  7. Vital parameter: Blood pressure (BP) [mmHg]

    Vital parameters will be used as a measure of safety to rule out adverse events of oxygen to the vascular system.

    Time frame: 3 hours

  8. Vital parameter: Oxygen saturation (SpO2) [%]

    Vital parameters will be used as a measure of safety to rule out adverse events of oxygen to the vascular system.

    Time frame: 3 hours

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Spelten O, Wetsch WA, Wrettos G, Kalenka A, Hinkelbein J. Response of rat lung tissue to short-term hyperoxia: a proteomic approach. Mol Cell Biochem. 2013 Nov;383(1-2):231-42. doi: 10.1007/s11010-013-1771-y. Epub 2013 Aug 11. PubMed 23934118 ↗
  • Hinkelbein J, Feldmann RE Jr, Kalenka A. Time-dependent alterations of cerebral proteins following short-term normobaric hyperoxia. Mol Cell Biochem. 2010 Jun;339(1-2):9-21. doi: 10.1007/s11010-009-0365-1. Epub 2010 Jan 5. PubMed 20049628 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 17, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02553668
Lead sponsor
University Hospital of Cologne
Responsible party
Dr. med. Stefan Braunecker (Anesthesiologist, University Hospital of Cologne) — Principal investigator
First posted
Sep 17, 2015
Start date
Oct 2015
Primary completion
Oct 2016 (estimated)
Completion
Dec 2016 (estimated)
Last update
Sep 17, 2015

Study contacts

Stefan Braunecker, M.D.
Contact
stefan.braunecker@uk-koeln.de
Jochen Hinkelbein, M.D.
Contact
jochen.hinkelbein@uk-koeln.de
Stefan Braunecker, M.D.
principal investigator · Universityhospital of Cologne

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion